Pacific Biosciences of California, Inc. (BMV:PACB)

BMV:PACB Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-546.38	-309.85	-306.74	-314.25	-181.22
Depreciation & Amortization	386.41	53.35	26.53	17.32	11.59
Asset Writedown & Restructuring Costs	15	184.5	-	-	-
Loss (Gain) From Sale of Investments	-4.37	-13.04	-12.84	-0.24	4.01
Stock-Based Compensation	41.67	71.04	72.12	78.61	73.36
Other Operating Activities	-7.99	-151.47	20.71	9.32	-39.24
Change in Accounts Receivable	-7.92	9.09	-17.83	5.46	-7.17
Change in Inventory	-1.42	-8.32	-13.84	-33.91	-13.11
Change in Accounts Payable	2.48	1.41	0.21	1.03	6.36
Change in Unearned Revenue	0.1	-2.11	-10.42	-3.73	25.74
Change in Other Net Operating Assets	11.2	-40.65	-17.07	-22.81	8.5
Operating Cash Flow	-111.21	-206.06	-259.17	-263.21	-111.18
Capital Expenditures	-2.71	-6.19	-8.84	-16.75	-5.93
Cash Acquisitions	-	-	-0.1	-	-319.79
Sale (Purchase) of Intangibles	-5	-	-	-0.18	-
Investment in Securities	123.16	130.19	13.55	133.01	-352.81
Investing Cash Flow	115.45	124	4.6	116.08	-678.53
Long-Term Debt Issued	-	-	-	-	895.54
Long-Term Debt Repaid	-	-50.69	-1.84	-1.61	-0.36
Net Debt Issued (Repaid)	-	-50.69	-1.84	-1.61	895.18
Issuance of Common Stock	3.43	7.7	204.52	11.23	326.65
Other Financing Activities	-	-	-93.79	-	-52.25
Financing Cash Flow	3.43	-42.99	108.89	9.62	1,170
Net Cash Flow	7.67	-125.04	-145.68	-137.51	379.87
Free Cash Flow	-113.92	-212.25	-268.02	-279.96	-117.11
Free Cash Flow Margin	-71.20%	-137.81%	-133.66%	-218.20%	-89.73%
Free Cash Flow Per Share	-0.38	-0.77	-1.06	-1.25	-0.57
Cash Interest Paid	8.26	14.81	15.69	14.05	6.93
Levered Free Cash Flow	97.55	-95.64	-311.67	46.5	-24.54
Unlevered Free Cash Flow	101.89	-87.26	-302.7	55.68	-16.71
Change in Working Capital	4.44	-40.58	-58.96	-53.97	20.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.